Burning Rock Biotech (BNR) Accumulated Expenses (2021 - 2023)

Burning Rock Biotech has reported Accumulated Expenses over the past 3 years, most recently at $14.6 million for Q4 2023.

  • Quarterly results put Accumulated Expenses at $14.6 million for Q4 2023, down 40.37% from a year ago — trailing twelve months through Dec 2023 was $14.6 million (down 40.37% YoY), and the annual figure for FY2023 was $14.8 million, down 42.91%.
  • Accumulated Expenses for Q4 2023 was $14.6 million at Burning Rock Biotech, down from $24.4 million in the prior quarter.
  • Over the last five years, Accumulated Expenses for BNR hit a ceiling of $24.4 million in Q4 2022 and a floor of $14.6 million in Q4 2023.
  • Median Accumulated Expenses over the past 3 years was $20.0 million (2021), compared with a mean of $19.7 million.
  • Biggest five-year swings in Accumulated Expenses: increased 22.19% in 2022 and later plummeted 40.37% in 2023.
  • Burning Rock Biotech's Accumulated Expenses stood at $20.0 million in 2021, then increased by 22.19% to $24.4 million in 2022, then plummeted by 40.37% to $14.6 million in 2023.
  • The last three reported values for Accumulated Expenses were $14.6 million (Q4 2023), $24.4 million (Q4 2022), and $20.0 million (Q4 2021) per Business Quant data.